Tri-Conference 2008
会议概要 展销前置会 地点 参展/赞助 大会议程 询问 报名
会议将同时进行
Fluidigm
Thermo
Aviva Systems Biology
Biobase
Caprion Proteomics
Expression Analysis
Ingenuity
Scientia Advisors
Theranostics Health
Tripos
Wafer GEN
CROWNBIO
Leomics Associates
PCO
BioCentury
Bio IT World
SCIENCE AAAS
TheScienteist




R&D Risk Mitigation 概要

[  概要   |   1日目   |   2日目   |   3日目   |   Catalog(PDF)  ]


第6回 降低研究开发之风险和价值创出战略 - 以共同合作、生物标靶及分子诊断为焦点
2008年3月25~27日

  1. 生化科技企业和制药公司的提携合作
  2. 研究开发平台、药剂候补、及分子诊断的价值创出
  3. 生物标靶对创药和新药开发的影响 (展开医疗之共同议程)
  4. 分子诊断中案例学习(分子诊断和癌的分子标靶之共同议程)

COMPREHENSIVE COVERAGE ON:

  • Valuing R&D Platforms & Drug Candidates

  • Impact of Biomarkers and Molecular Profiling on Discovery & Development

  • Case Studies in Companion Diagnostics

  • Measuring Developing Markets

PLENARY KEYNOTE SPEAKERS

Diagnosing the Disease: Disruptive Innovation in Healthcare
Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School

 

 

Risk Diagnosis forDisease Prevention
C. Thomas Caskey, M.D., F.A.C.P., Director and Chief Executive Officer, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center

 

 

Disruption of the Pharmaceutical Industry: Moving from Products to Solutions
Elizabeth L. Bewley, MBA, Vice President, Strategic Planning, Johnson & Johnson Health Care Systems Inc.

FEATURED Organizations

  • AstraZeneca

  • Banner & Witcoff, Ltd.

  • Bristol-Myers Squibb

  • Burrill & Company

  • Centocor R&D, Inc.

  • Cepheid

  • Esoterix Clinical Trials Services

  • Food & Drug Administration

  • Johnson and Johnson B.I.O.

  • Medicines Ltd.

  • National Cancer Institute

  • National Institutes of Health

  • Pfizer Global Research and Development

  • Pfizer Worldwide Business Development

  • Roche Applied Science

Catalog(PDF) Download
Schedule

语言选择